Date created: | Last Updated:

Category: Project

Description: Background: Gestational trophoblastic neoplasia represents a rare placental malignancy spectrum that is treated with single-agent or multi-agent chemotherapy. This disease often impacts women of childbearing age, making post-chemotherapy fertility and obstetrical outcomes an important consideration. Approximately 25 of gestational trophoblastic neoplasia tumors will be recurrent to, or will relapse after, initial chemotherapy. These resistant and recurrent lesions will require salvage chemotherapy with or without surgery. Therefore, we will conduct this study to assess the efficiency and safety of chemotherapy in treating women with resistant or recurrent gestational trophoblastic neoplasia. Methods: We will conduct a systematic review of randomized controlled trials evaluating the efficiency and safety of chemotherapy in treating women with resistant or recurrent gestational trophoblastic neoplasia. We will search MEDLINE, Web of Science, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), and WanFang database from their inception to May 2021. A manual search in the bibliographies of eligible studies and relevant systematic reviews will conduct to identify additional relevant studies. Two authors will independently review study titles/abstract for eligibility, followed by full-text screening. We will use the standardized data extraction table to extract study data. Meanwhile, we will use the Cochrane Risk of Bias Tool to assess the risk of bias of included studies. Results: A high-quality synthesis of current evidence of chemotherapy in treating women with resistant or recurrent gestational trophoblastic neoplasia will be provided in the present study. Conclusion: The study will provide updated evidence to assess the efficiency and safety of chemotherapy in treating women with resistant or recurrent gestational trophoblastic neoplasia.